Piper Jaffray Sticks to Their Hold Rating for Endo International

By Ryan Adsit

Piper Jaffray analyst David Amsellem reiterated a Hold rating on Endo International (NASDAQ: ENDP) on September 15 and set a price target of $9. The company’s shares closed on Friday at $8.60, close to its 52-week low of $7.41.

According to TipRanks.com, Amsellem is a 1-star analyst with an average return of -0.9% and a 46.7% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Amphastar Pharmaceuticals.

Currently, the analyst consensus on Endo International is Hold and the average price target is $12.33, representing a 43.4% upside.

In a report issued on September 6, Canaccord Genuity also maintained a Hold rating on the stock with a $10 price target.

Based on Endo International’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $876 million and GAAP net loss of $1.4 billion. In comparison, last year the company earned revenue of $921 million and had a net profit of $344 million.

Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ENDP in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The company operates through the following segments: U.S. Branded Pharmaceuticals, U.S. Generic pharmaceuticals and International Pharmaceuticals. The U.S.